Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma

OBJECTIVE: This study was designed to determine the safety, pharmacokinetics and biologic effects of a human-mouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese patients with CD20-positive B-cell non-Hodgkin's lymphoma (CD20(+) B-cell NHL). SCT400 has an identical amino acid sequen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chin J Cancer Res
Autors principals: Gui, Lin, Han, Xiaohong, He, Xiaohui, Song, Yuanyuan, Yao, Jiarui, Yang, Jianliang, Liu, Peng, Qin, Yan, Zhang, Shuxiang, Zhang, Weijing, Gai, Wenlin, Xie, Liangzhi, Shi, Yuankai
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865612/
https://ncbi.nlm.nih.gov/pubmed/27199517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2016.02.07
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars